Business
-
Launched officially on January 1, 2012, Lustren Consulting is now offering “specialist management consultancy for device development in the healthcare industry” with particular expertise in inhalation device development. The company, which was unofficially introduced at… Read more . . .
-
The European Patent Office has granted patent number EP 2315580 B1 to Massachusetts biotech company Pulmatrix for “Pharmaceutical formulations and methods for treating respiratory tract infections.” The patent covers “both dry powder and liquid formulations… Read more . . .
-
California-based Elevation Pharmaceuticals has announced closing of $30 million in Series B financing for development of its lead product, EP-101, a glycopyrrolate inhalation solution for the treatment of COPD. Novo Ventures, a new investor, led… Read more . . .
-
Pharmaxis has announced that it “filed a minor resubmission with the Pharmaceutical Benefits Advisory Committee (PBAC)” for its Bronchitol mannitol dry powder inhaler for the treatment of cystic fibrosis. According to the company, the committee’s… Read more . . .
-
Days after an FDA committee recommended approval of its lead product, Adasuve inhaled loxapine for the treatment of agitation in schizophrenia or bipolar disorder, Alexza Pharmaceuticals has announced that it is “exploring strategic options to… Read more . . .
-
Effective January 1 2012, the Seretide salmeterol xinafoate/fluticasone propionate Accuhaler 100 will cost £18 in the UK, a reduction of 42%. The price reduction is expected to save the National Health Service (NHS) £6.9 million… Read more . . .
-
ISTA Pharmaceuticals has rejected an unsolicited, non-binding proposal from Valeant Pharmaceuticals to acquire all of its outstanding shares on the grounds that the offer “was grossly inadequate.” ISTA’s board voted unanimously against the proposal. The… Read more . . .
-
According to MannKind Corporation, it has completely resolved arbitration initiated by a lawsuit filed by its former Senior Director – GCP – Regulatory Affairs, John Arditi, in 2010. Arditi, who had been responsible for MannKind’s… Read more . . .
-
US Patent No. 8,076,290 regarding stabilized formulations of parathyroid hormone (PTH) and PTH peptide analogs for various means of delivery, including intranasal delivery, has been awarded to Aegis Therapeutics. PTH and PTH peptide analogs such… Read more . . .
-
The United States Patent and Trademark Office has issued US Patent No. 8,071,127 regarding formulations of inhaled liposomal and free ciprofloxacin to Aradigm Corporation. The patent covers the company’s lead candidate, Pulmaquin dual release ciprofloxacin… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden